A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study ...

U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease ...

Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as ...

The notice adds to growing concerns about the safety of knockoff weight loss drugs, which have remained popular despite FDA ...

Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top ...

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...

Yet one factor remains consistently underestimated: physical connectivity or fluid management. The tubing, connectors, ...

Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, ...

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...

Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug ...

The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi ...

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a ...